Cargando…

Sociodemographic and Illness-Related Indicators to Predict the Status of Neuromyelitis Optica Spectrum Disorder (NMOSD) Five Years after Disease Onset

Background: Neuromyelitis Optica Spectrum Disorder (NMOSD) is an autoimmune demyelinating disease of the central nervous system. Currently, no factors have been identified to predict the long-term course of NMOSD. To counter this, we analyzed data of 58 individuals with NMOSD at disease onset and ab...

Descripción completa

Detalles Bibliográficos
Autores principales: Sadeghi-Bahmani, Dena, Barzegar, Mahdi, Mirmosayyeb, Omid, Vaheb, Saeed, Nehzat, Nasim, Shaygannejad, Vahid, Brand, Serge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836947/
https://www.ncbi.nlm.nih.gov/pubmed/35160189
http://dx.doi.org/10.3390/jcm11030734
_version_ 1784649802895589376
author Sadeghi-Bahmani, Dena
Barzegar, Mahdi
Mirmosayyeb, Omid
Vaheb, Saeed
Nehzat, Nasim
Shaygannejad, Vahid
Brand, Serge
author_facet Sadeghi-Bahmani, Dena
Barzegar, Mahdi
Mirmosayyeb, Omid
Vaheb, Saeed
Nehzat, Nasim
Shaygannejad, Vahid
Brand, Serge
author_sort Sadeghi-Bahmani, Dena
collection PubMed
description Background: Neuromyelitis Optica Spectrum Disorder (NMOSD) is an autoimmune demyelinating disease of the central nervous system. Currently, no factors have been identified to predict the long-term course of NMOSD. To counter this, we analyzed data of 58 individuals with NMOSD at disease onset and about five years later. Methods: Medical records of 58 individuals with NMOSD (mean age: 31.13 years at disease onset; 86.2% female) were retrospectively analyzed. At baseline, a thorough medical and disease-related examination was performed; the same examination was repeated about five years later at follow-up, including treatment-related information. Mean outcome measure was the difference in EDSS (Expanded Disease Severity Scale) scores between baseline and follow-up. Results: Mean disease duration was 4.67 years. Based on the differences of the EDSS scores between baseline and follow-up, participants were categorized as improving (n = 39; 67.2%), unchanged (n = 13; 22.4%) and deteriorating (n = 6; 10.3%). Deteriorating was related to a higher progression index, and a higher number of attacks, while the annualized relapse rate reflecting the number of attacks per time lapse did not differ between the three groups. Improving was related to a higher intake of rituximab, and to a higher rate of seropositive cases. Unchanged was related to a lower rate of seropositive cases. Factors such as age, gender, somatic and psychiatric comorbidities, symptoms at disease onset, relapse rates, number and location of cervical plaques, or brain plaques and thoracolumbar plaques at baseline did not differ between those improving, deteriorating or remaining unchanged. Conclusions: Among a smaller sample of individuals with NMOSD followed-up about five years later, individuals deteriorating over time reported a higher progression index, while the annualized relapse rate was unrelated to the progress of disease. Overall, it appears that the course of NMOSD over a time lapse of about five years after disease onset is highly individualized. Accordingly, treatment regimen demands a highly individually tailored approach.
format Online
Article
Text
id pubmed-8836947
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88369472022-02-12 Sociodemographic and Illness-Related Indicators to Predict the Status of Neuromyelitis Optica Spectrum Disorder (NMOSD) Five Years after Disease Onset Sadeghi-Bahmani, Dena Barzegar, Mahdi Mirmosayyeb, Omid Vaheb, Saeed Nehzat, Nasim Shaygannejad, Vahid Brand, Serge J Clin Med Article Background: Neuromyelitis Optica Spectrum Disorder (NMOSD) is an autoimmune demyelinating disease of the central nervous system. Currently, no factors have been identified to predict the long-term course of NMOSD. To counter this, we analyzed data of 58 individuals with NMOSD at disease onset and about five years later. Methods: Medical records of 58 individuals with NMOSD (mean age: 31.13 years at disease onset; 86.2% female) were retrospectively analyzed. At baseline, a thorough medical and disease-related examination was performed; the same examination was repeated about five years later at follow-up, including treatment-related information. Mean outcome measure was the difference in EDSS (Expanded Disease Severity Scale) scores between baseline and follow-up. Results: Mean disease duration was 4.67 years. Based on the differences of the EDSS scores between baseline and follow-up, participants were categorized as improving (n = 39; 67.2%), unchanged (n = 13; 22.4%) and deteriorating (n = 6; 10.3%). Deteriorating was related to a higher progression index, and a higher number of attacks, while the annualized relapse rate reflecting the number of attacks per time lapse did not differ between the three groups. Improving was related to a higher intake of rituximab, and to a higher rate of seropositive cases. Unchanged was related to a lower rate of seropositive cases. Factors such as age, gender, somatic and psychiatric comorbidities, symptoms at disease onset, relapse rates, number and location of cervical plaques, or brain plaques and thoracolumbar plaques at baseline did not differ between those improving, deteriorating or remaining unchanged. Conclusions: Among a smaller sample of individuals with NMOSD followed-up about five years later, individuals deteriorating over time reported a higher progression index, while the annualized relapse rate was unrelated to the progress of disease. Overall, it appears that the course of NMOSD over a time lapse of about five years after disease onset is highly individualized. Accordingly, treatment regimen demands a highly individually tailored approach. MDPI 2022-01-29 /pmc/articles/PMC8836947/ /pubmed/35160189 http://dx.doi.org/10.3390/jcm11030734 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sadeghi-Bahmani, Dena
Barzegar, Mahdi
Mirmosayyeb, Omid
Vaheb, Saeed
Nehzat, Nasim
Shaygannejad, Vahid
Brand, Serge
Sociodemographic and Illness-Related Indicators to Predict the Status of Neuromyelitis Optica Spectrum Disorder (NMOSD) Five Years after Disease Onset
title Sociodemographic and Illness-Related Indicators to Predict the Status of Neuromyelitis Optica Spectrum Disorder (NMOSD) Five Years after Disease Onset
title_full Sociodemographic and Illness-Related Indicators to Predict the Status of Neuromyelitis Optica Spectrum Disorder (NMOSD) Five Years after Disease Onset
title_fullStr Sociodemographic and Illness-Related Indicators to Predict the Status of Neuromyelitis Optica Spectrum Disorder (NMOSD) Five Years after Disease Onset
title_full_unstemmed Sociodemographic and Illness-Related Indicators to Predict the Status of Neuromyelitis Optica Spectrum Disorder (NMOSD) Five Years after Disease Onset
title_short Sociodemographic and Illness-Related Indicators to Predict the Status of Neuromyelitis Optica Spectrum Disorder (NMOSD) Five Years after Disease Onset
title_sort sociodemographic and illness-related indicators to predict the status of neuromyelitis optica spectrum disorder (nmosd) five years after disease onset
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836947/
https://www.ncbi.nlm.nih.gov/pubmed/35160189
http://dx.doi.org/10.3390/jcm11030734
work_keys_str_mv AT sadeghibahmanidena sociodemographicandillnessrelatedindicatorstopredictthestatusofneuromyelitisopticaspectrumdisordernmosdfiveyearsafterdiseaseonset
AT barzegarmahdi sociodemographicandillnessrelatedindicatorstopredictthestatusofneuromyelitisopticaspectrumdisordernmosdfiveyearsafterdiseaseonset
AT mirmosayyebomid sociodemographicandillnessrelatedindicatorstopredictthestatusofneuromyelitisopticaspectrumdisordernmosdfiveyearsafterdiseaseonset
AT vahebsaeed sociodemographicandillnessrelatedindicatorstopredictthestatusofneuromyelitisopticaspectrumdisordernmosdfiveyearsafterdiseaseonset
AT nehzatnasim sociodemographicandillnessrelatedindicatorstopredictthestatusofneuromyelitisopticaspectrumdisordernmosdfiveyearsafterdiseaseonset
AT shaygannejadvahid sociodemographicandillnessrelatedindicatorstopredictthestatusofneuromyelitisopticaspectrumdisordernmosdfiveyearsafterdiseaseonset
AT brandserge sociodemographicandillnessrelatedindicatorstopredictthestatusofneuromyelitisopticaspectrumdisordernmosdfiveyearsafterdiseaseonset